Close menu




January 26th, 2024 | 07:00 CET

Drumbeats and Buy recommendations: Siemens Energy, SAP, Cardiol Therapeutics

  • Biotechnology
  • Energy
  • AI
Photo credits: pixabay.com

Analysts at First Berlin see over 200% upside potential for the Cardiol Therapeutics share. The biotech pearl is solidly financed to implement its development pipeline. Positive Phase II data and FDA approval for a Phase III trial are expected in the second quarter of 2024, which should drive the share price. Yesterday's top performers included the shares of Siemens Energy and SAP. At Siemens Energy, the situation at subsidiary Gamesa does not appear to be as catastrophic as feared. SAP is fully committed to the Cloud and AI. Shareholders do not seem bothered by the additional costs for the transformation in 2024; instead, they are celebrating future growth opportunities.

time to read: 3 minutes | Author: Fabian Lorenz
ISIN: SIEMENS ENERGY AG NA O.N. | DE000ENER6Y0 , SAP SE O.N. | DE0007164600 , CARDIOL THERAPEUTICS | CA14161Y2006

Table of contents:


    David Elsley, CEO, Cardiol Therapeutics Inc.
    "[...] As a company dedicated to developing treatments for rare heart diseases, we see this as an opportune moment to contribute to the fight against heart disease and make meaningful strides in improving heart health worldwide. [...]" David Elsley, CEO, Cardiol Therapeutics Inc.

    Full interview

     

    Cardiol Therapeutics: Analysts expect share price jump with positive trial results

    The analysts at First Berlin have reiterated their "Buy" recommendation for Cardiol Therapeutics shares. The price target is USD 3.60. The shares are currently trading at around USD 1.12. The experts believe that Cardiol shares have an upside potential of over 200%. Cardiol Therapeutics focuses on researching and developing therapies for cardiovascular diseases. The Company is well financed to implement its development strategy. At the beginning of the upcoming quarter, experts expect Cardiol to publish positive data from the ongoing Phase II pilot study of CardiolRx™ for the indication of recurrent pericarditis - inflammation of the pericardium. Patients from eight heart centers in the US are participating in the study. These sites include the renowned Cleveland Clinic, Massachusetts General Hospital and the Mayo Clinic. Shortly after the positive data, FDA approval for the Phase III trial could be granted, which should trigger a jump in the share price.

    In addition, the international Phase II trial to prove the efficacy of CardiolRx™ in acute myocarditis (inflammation of the heart muscle) is also being driven forward. The recruitment rate rose over 50% in January 2024, therefore Cardiol is well on track to recruit all the patients it needs by the beginning of the third quarter of 2024 and to publish initial results before the end of the year.

    Important for research-based biotech companies is the cash position; in this regard, Cardiol is in a solid position. At the end of the third quarter 2023, the Canadians had cash and cash equivalents of more than CAD 40 million. That corresponds to around 40% of the market capitalization. Cardiol should, therefore, be fully financed for the coming years.

    SAP: Expects more than analysts

    SAP has made a significant announcement, revealing plans to focus even more on AI and exceed analysts' earnings expectations by 2025. To this end, a transformation program has been announced. This year, SAP intends to focus even more strongly on key strategic growth areas, particularly AI for companies. The operational structures are also to be redesigned in order to exploit organizational synergy effects, achieve efficiency gains through AI and prepare the Company for highly scalable future revenue growth. Around 8,000 employees will be directly affected by the measures. They will be offered voluntary programs and internal retraining measures. The number of employees is not expected to change until the end of 2024. The restructuring costs are provisionally expected to amount to around EUR 2 billion and will largely be recognized in the first half of 2024.

    Due to the strong performance in the fourth quarter of 2023, the updated non-IFRS definition of earnings measures and the expected benefits from the transaction program, SAP is also revising its forecasts for 2025. In the coming year, SAP aims to achieve an operating profit (non-IFRS) of around EUR 10 billion and a free cash flow of EUR 8 billion. Both targets exceed the consensus estimates of analysts.

    Siemens Energy: Gamesa with less loss than expected

    Siemens Energy has also surprised investors with an ad hoc announcement. The ailing company has announced preliminary figures for the first quarter of the 2023/24 financial year. The preliminary financial results are above market expectations. The Gas Services, Grid Technologies and Transformation of Industry divisions, in particular, are developing positively.

    Overall, Siemens Energy expects the market environment to remain positive. The Group is, therefore, maintaining its forecast for the full year 2023/24. Comparable revenue growth (excluding currency translation and portfolio effects) is expected to be between 3% and 7%. The earnings margin before special items is expected to be between -2% and 1%.

    In the first quarter, sales rose from EUR 7.1 billion to EUR 7.6 billion compared to the same period of the previous year. Analyst consensus estimates were at EUR 7.4 billion. Earnings before special items improved from EUR -282 million to EUR 208 million. Analysts had expected EUR -106 million.

    It is also interesting to look at the weakening subsidiary Siemens Gamesa, where earnings before special items amounted to an impressive EUR -426 million, but this was better than the EUR -576 million expected by analysts.


    Yesterday's jump in the share price of Siemens Energy shows that the figures were well received. The development at Siemens Gamesa may not be as catastrophic as initially assumed. In addition, the other divisions seem to be doing well. The focus of SAP on Cloud and AI is going down well with investors. Although there are higher costs in the current year, it should pay off in the coming year. Investors may still need a little patience with Cardiol. However, with positive study results, there could be a quick and significant upward movement.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Fabian Lorenz

    For more than twenty years, the Cologne native has been intensively involved with the stock market, both professionally and privately. He is particularly passionate about national and international small and micro caps.

    About the author



    Related comments:

    Commented by André Will-Laudien on February 20th, 2024 | 07:30 CET

    Takeover fever in the biotech sector! Will MorphoSys now be followed by Defence Therapeutics, Evotec and Bayer?

    • Biotechnology
    • Pharma
    • Innovations

    It has happened: Novartis is bidding for MorphoSys. Once again, a long-lasting and persistent rumour mill eventually confirms itself. Those who remained loyal to MorphoSys despite heavy selling last fall have now made a profit of over 300%. If we turn the analytical magnifying glass on the sector, we can see that the speculative biotech stock market segment has started to move again since the challenging year 2023. Hopes of falling interest rates in the near future, along with several other M&A hopes, have led to steady inflows into listed bio-ETFs, resulting in fund managers having recently adjusted their weightings upwards. We analyze which stocks are currently making the loudest noise.

    Read

    Commented by André Will-Laudien on February 16th, 2024 | 07:00 CET

    MorphoSys and Cardiol Therapeutics in upward mode, while Bayer and Pfizer are in slow mode

    • Biotechnology
    • Pharma

    The biotech sector has made a very differentiated start to the new year. While the old favorites are barely moving, the second-line stocks MorphoSys and Cardiol Therapeutics are making a real splash. At Bayer, the bad news just won't go away, and despite a successful major takeover, Pfizer has not yet found its forward gear. After a rally of almost 15% in December, the Nasdaq Biotechnology Index (NBI) has taken a pause in the current year. Now, everyone is waiting for the first interest rate cut by central banks. Inflation is already falling, and the negative economic data for the Eurozone is increasing. The ECB would normally be in demand. What should investors urgently keep an eye on?

    Read

    Commented by Armin Schulz on February 14th, 2024 | 07:30 CET

    Nel ASA, Klimat X Developments, Nordex - Climate Neutral: The Business Booster

    • Sustainability
    • renewableenergies
    • Energy

    In a world that is increasingly scrutinizing the ecological footprint of business ventures, companies that actively integrate measures to achieve climate neutrality into their business processes are increasingly coming into focus. Such proactive companies can gain a significant competitive advantage in the current environment. It is not only end consumers who are increasingly paying attention to the climate neutrality of companies but also the companies themselves. Being climate-neutral enhances the value of one's brand, providing an additional selling point, and green companies receive bonus points in financing discussions. We take a look at three companies that are trying to make the world a greener place.

    Read